The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD ...

At Week 72, the first primary endpoint showed 62.9% of people treated with semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% on ...

A confirmatory secondary endpoint at Week 72 showed 32.7% of patients treated with semaglutide 2.4 mg achieved both resolution of steatohepatitis and improvement in liver fibrosis compared to 16.1 ...

25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

Ozempic copycats could come with hefty price tags as FDA declares end of semaglutide shortage Trump blames Zelensky for derailing London peace talks 20 Beautiful Baby Names From the 1940s That ...